Rhythm Pharmaceuticals (RYTM) Revenue (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Revenue data on file, last reported at $60.1 million in Q1 2026.

• On a quarterly basis, Revenue rose 83.81% year-over-year to $60.1 million in Q1 2026; TTM through Mar 2026 was $217.2 million, a 58.67% increase from a year earlier, with the FY2025 full-year figure at $189.8 million, up 45.83% from the prior year.
• Revenue for Q1 2026 stood at $60.1 million, up from $57.3 million in the prior quarter.
• Over the last five years, Revenue for RYTM reached as high as $60.1 million in Q1 2026 and fell as low as -$8.0 million in Q4 2022.
• Historically, Revenue has averaged $27.3 million across 5 years, with a median of $26.0 million in 2024.
• On a YoY basis, Revenue climbed as much as 4180.0% in 2022 and fell as far as 542.93% in 2022.
• Year by year, Revenue stood at -$8.0 million in 2022, then surged by 401.12% to $24.2 million in 2023, then surged by 72.61% to $41.8 million in 2024, then jumped by 36.87% to $57.3 million in 2025, then grew by 4.99% to $60.1 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $60.1 million in Q1 2026, $57.3 million in Q4 2025, and $51.3 million in Q3 2025.